Omada Health's Earnings: A Test of Virtual Care's Profitability

SAN FRANCISCO, CA – February 09, 2026 – Omada Health (Nasdaq: OMDA) has set the stage for a pivotal moment in its journey as a public company, announcing it will release its fourth-quarter and full-year 2025 financial results on March 5, 2026. The announcement, a standard-issue disclosure for a publicly traded firm, carries significant weight for investors and the broader digital health industry, who will be scrutinizing the results for signs of sustainable growth and a clear path to profitability in the competitive virtual chronic care market.

Following the release, the company's leadership will host a conference call, offering a crucial platform to detail its performance and field questions from analysts. The upcoming report follows a year of significant milestones for Omada, including a successful IPO and its first-ever quarter of positive adjusted EBITDA, making the March 5th disclosure a key barometer for the company's trajectory and the viability of its high-touch, tech-enabled care model.

A Crucial Test on the Path to Profitability

Investors will be closely watching to see if Omada can build upon the momentum established in 2025. The company, which went public in June 2025 with an IPO that raised $150 million, has been on a mission to prove it can scale effectively. The third quarter of 2025 marked a significant turning point, with Omada reporting its first positive adjusted EBITDA of $2 million on revenues of $68 million, a 49% year-over-year increase. This achievement signaled a potential shift from a growth-at-all-costs mindset to one focused on financial discipline.

Despite this milestone, the company's stock has experienced considerable volatility, declining significantly from its IPO price of $19 per share. This suggests that while investors are encouraged by top-line growth, they remain cautious, seeking confirmation that profitability is not a fleeting anomaly. The company has already provided preliminary, unaudited revenue figures for the fourth quarter, expecting between $72 million and $74 million, which would bring its full-year 2025 revenue to a range of $251.5 million to $254.5 million, aligning with prior guidance.

While revenue growth is strong, the focus will undoubtedly be on the bottom line. Omada has successfully narrowed its net losses from $67.5 million in 2023 to $47.1 million in 2024, with Q3 2025 net loss shrinking to just $3 million. Analysts, who hold a consensus "Moderate Buy" rating on the stock with an average price target of $25.10, will be looking for continued progress in this area. The upcoming earnings call will be an opportunity for leadership to demonstrate that improved gross margins, which climbed to 66% in Q3, and operational efficiencies are creating a durable financial model.

Beyond the Numbers: A Strategy for the Modern Patient

Omada Health's financial performance is intrinsically linked to its unique operational strategy, which it describes as providing "between-visit healthcare." The company targets the most prevalent and costly chronic conditions plaguing the healthcare system: obesity, diabetes, hypertension, and musculoskeletal issues. Its virtual-first model is a sophisticated blend of human interaction and advanced technology, aiming to fix what it calls a system that "poorly serves chronic conditions."

At the core of its offering are human-led care teams—coaches, specialists, and clinicians—who provide personalized support to members. This human touch is augmented by a suite of connected devices, such as smart scales, blood pressure monitors, and continuous glucose monitors, which feed real-time data into the platform. An AI-enabled engine then analyzes this data to personalize interventions, tailor educational content, and help care teams prioritize their efforts, a model the company calls "Compassionate Intelligence."

This integrated approach has allowed Omada to scale its services to over one million members across more than 2,000 customers, including employers, health plans, and health systems. The company's ability to demonstrate strong clinical outcomes and high member engagement is central to its value proposition and a key driver of its impressive 90%+ customer retention rate.

Capitalizing on the GLP-1 Wave

A critical component of Omada's recent strategy has been its proactive integration with the burgeoning market for GLP-1 (Glucagon-like Peptide-1) therapies. The meteoric rise of drugs like Ozempic and Wegovy for diabetes and weight management has created a massive new market, but also a new challenge: ensuring patients using these powerful medications receive the necessary behavioral support to achieve long-term success.

Recognizing this, Omada developed its GLP-1 Care Tracks, specialized companion programs designed to support members on these therapies. These programs provide the coaching, nutritional guidance, and lifestyle modification support that medication alone cannot offer. This strategic move positions Omada not as a competitor to pharmaceuticals, but as an essential partner in optimizing their effectiveness and managing their high cost.

This approach has gained significant traction. Omada has secured partnerships to make its GLP-1 companion programs available through two of the largest pharmacy benefit managers in the United States, granting it access to a vast population of potential users. This foresight allows the company to capitalize on one of the most significant trends in modern medicine, turning a market disruption into a powerful growth driver.

The Competitive Landscape and Investor Outlook

Omada operates in a crowded and fiercely competitive digital health space, vying with giants like Teladoc Health and other specialized chronic care providers like DarioHealth. In this environment, differentiation is key. While many competitors offer digital tools, Omada's emphasis on human-led care combined with its scalable tech platform and strategic GLP-1 integration helps it stand out.

The entire digital health sector has faced investor skepticism regarding profitability. Many companies have struggled to translate user growth into sustainable earnings, making Omada's recent positive adjusted EBITDA a notable achievement within the industry. However, the market's reaction to its Q3 results—a slight dip in stock price despite the positive news—underscores the high expectations placed upon the company.

As the March 5th conference call approaches, investors and analysts will be listening for more than just numbers. They will want a clear narrative on how Omada plans to maintain its growth in member count and revenue while continuing its march toward consistent GAAP profitability. Key questions will revolve around the adoption rates of its GLP-1 programs, the expansion of its partnerships with health plans and employers, and its strategy for managing costs as it continues to scale. The answers provided will likely set the tone for the company's valuation and market sentiment for the year ahead.